DNMT3A and myeloid neoplasm: For example, Park and Yoshizato [7–9] showed that the most common mutations in AA patients were BCORL1/BCOR, ASXL1, DNMT3A and TET2, among which AA patients with myeloid tumor-related mutations, such as ASXL1, DNMT3A, RUNX1, showed approximately 40-60% response and overall survival after IST.